Prognositc Factors in COVID-19 Patients Complicated With Hypertension
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04272710|
Recruitment Status : Withdrawn (Similar projects have been registered, and it need to be withdrawn.)
First Posted : February 17, 2020
Last Update Posted : March 17, 2020
|Condition or disease|
At present, the outbreak of the new coronavirus (2019-nCoV) infection in Wuhan and Hubei provinces has attracted great attention from the medical community across the country. Both 2019-nCoV and SARS viruses are coronaviruses, and they have a large homology.
Published laboratory studies have suggested that SARS virus infection and its lung injury are related to angiotensin-converting enzyme 2 (ACE2) in lung tissue. And ACE and ACE2 in the renin-angiotensin system (RAS) are vital central links to maintain hemodynamic stability and normal heart and kidney function in vivo.
A large amount of evidence-based medical evidence shows that ACE inhibitors are the basic therapeutic drugs for maintaining hypertension, reducing the risk of cardiovascular, cerebrovascular, and renal adverse events, improving quality of life, and prolonging life in patients with hypertension. Recent experimental studies suggest that treatment with ACE inhibitors can significantly reduce pulmonary inflammation and cytokine release caused by coronavirus infection.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Prognostic Characteristics Difference Between the Hypertension Patients With and Without ACEI Treatment When Suffered With 2019-nCoV Infection in China|
|Actual Study Start Date :||January 25, 2020|
|Estimated Primary Completion Date :||March 31, 2020|
|Estimated Study Completion Date :||April 30, 2020|
hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China
- Occupancy rate in the intensive care unit (ICU) [ Time Frame: up to 28 days ]The percentage of patients admitted to the ICU at any time during the 28 days of onset COVID-19.
- Mechanical Ventilation [ Time Frame: up to 28 days ]The number of patients requiring mechanical ventilation.
- Death [ Time Frame: up to 28 days ]The number of patients who died of 2019-nCoV infection.
- All cause mortality [ Time Frame: up to 28 days ]The number of died 2019-nCoV infected patients from any cause.
- Time from onset of symptoms to main outcome and its components [ Time Frame: up to 28 days ]Time from onset of symptoms to admitted to the ICU, requiring mechanical ventilation, and death.
- Time to Clinical Recovery [ Time Frame: up to 28 days ]Time to Clinical Recovery
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04272710
|The First Affiliated Hospital of Chongqing Medical University|